Skip to main content
. 2019 Jan 28;10(2):91. doi: 10.1038/s41419-019-1322-x

Fig. 4. Targeting the transcriptional activation of 3-hydroxy-3-methylglutaryl-CoA (HMGCR) sensitizes statin-resistant breast cancer cells to atorvastatin (ATO), simvastatin (SIM), and rosuvastatin (ROSU).

Fig. 4

Human MCF-7, T47D and MDA-MB-231 breast cancer cells were treated with different statins. Sterol regulatory element-binding protein 2 (SREBP-2) protein expression was analyzed using Western blot (a). MCF-7 and T47D cells were treated with statins and dipyridamole for 48 h. Cell vitality was measured using the CellTiterBlue® assay (b, c). Adherent breast cancer cells were stained with crystal violet after treatment and absorbance was measured at 595 nm after elution with 10% SDS (b, d). Protein expression of HMGCR and cleaved poly-ADP ribose polymerase (PARP) was investigated using Western blot analysis. Representative images are shown (b). Data are shown as mean ± SD of at least three individual experiments. (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)